Compare CERS & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CERS | BBNX |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 585.1M | 493.1M |
| IPO Year | 1996 | N/A |
| Metric | CERS | BBNX |
|---|---|---|
| Price | $3.12 | $16.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $23.80 |
| AVG Volume (30 Days) | ★ 2.9M | 1.1M |
| Earning Date | 04-30-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.27 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $51,326,000.00 | N/A |
| Revenue This Year | $19.95 | $34.90 |
| Revenue Next Year | $8.84 | $34.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 30.68 | N/A |
| 52 Week Low | $1.15 | $8.80 |
| 52 Week High | $3.21 | $32.71 |
| Indicator | CERS | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 69.04 | 67.27 |
| Support Level | $2.37 | $16.02 |
| Resistance Level | N/A | $32.52 |
| Average True Range (ATR) | 0.17 | 1.07 |
| MACD | 0.04 | 0.16 |
| Stochastic Oscillator | 94.34 | 89.90 |
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.